Ignite Creation Date:
2024-05-06 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 2:14 PM
Study NCT ID:
NCT05051904
Status:
COMPLETED
Last Update Posted:
2024-03-07
First Post:
2021-09-15
Brief Title:
A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran Rivaroxaban or Warfarin
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
Comparative Safety and Effectiveness of Warfarin Dabigatran and Rivaroxaban Among Japanese Patients With Non-valvular Atrial Fibrillation NVAF and Concomitant Coronary Artery Disease CAD
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study aims to evaluate the safety and effectiveness comparisons between warfarin dabigatran and rivaroxaban in routine clinical practice among Japanese non-valvular atrial fibrillation NVAF patients with concomitant coronary artery disease CAD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None